quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:50:55·198d
INSIDERFiling
Alzamend Neuro Inc. logo

Director Ault Milton C Iii sold $344,222 worth of shares (139,412 units at $2.47) and converted options into 200,000 shares (SEC Form 4)

ALZN· Alzamend Neuro Inc.
Health Care
Original source

Companies

  • ALZN
    Alzamend Neuro Inc.
    Health Care

Recent analyst ratings

  • Oct 1UpdateAscendiant Capital Markets$8.00

Related

  • SEC6d
    Alzamend Neuro Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • INSIDER7d
    SEC Form 4 filed by Ault Milton C Iii
  • PR17d
    Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
  • PR29d
    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
  • SEC34d
    Alzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
  • PR39d
    Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
  • SEC43d
    SEC Form 10-Q filed by Alzamend Neuro Inc.
  • SEC48d
    SEC Form 424B5 filed by Alzamend Neuro Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022